Antibiotics have been a cornerstone of modern medicine, saving countless lives from bacterial infections. However, concerns have been raised about their impact on the developing immune system, especially during prenatal development and early infancy. These concerns stem from hypotheses about the intricate interplay between microbiome alterations and immune regulation, suggesting that disrupting the natural establishment of microbial communities might set the stage for autoimmune pathologies later in life. Previous observational studies hinted at an increased risk of autoimmune diseases following early antibiotic exposure, but their findings were often limited by confounding variables, small sample sizes, or incomplete data on timing and dosage of antibiotic use.

To cut through the noise, Shin and colleagues leveraged the comprehensive South Korea National Health Insurance Service-National Health Insurance Database (NHIS-NHID). This mother-child linked insurance claims database allowed researchers to identify cohorts of children born between April 2009 and December 2020 whose mothers received antibiotic prescriptions during pregnancy or while breastfeeding. By tracking these children’s health outcomes longitudinally for over seven years, the study encompassed data on diagnoses of multiple autoimmune diseases, including Type 1 diabetes, juvenile idiopathic arthritis, inflammatory bowel diseases (such as ulcerative colitis and Crohn’s disease), systemic lupus erythematosus, and Hashimoto’s thyroiditis.

The statistical analyses employed adjusted for a wide range of potential confounders, including maternal health conditions, socioeconomic factors, and delivery methods, to isolate the specific effect of antibiotic exposure. Remarkably, the findings revealed no significant increase in the overall incidence of autoimmune diseases among children exposed to antibiotics either prenatally or during early infancy. This null association persisted across diverse autoimmune conditions studied and held true even when stratified by the timing and extent of antibiotic use.

These results stand in contrast to earlier studies that reported a possible link between early antibiotic exposure and autoimmune risk. Shin et al. emphasize that such discrepancies likely reflect differing research methodologies, population characteristics, and the complexities inherent in immune system development. They caution against oversimplified conclusions, suggesting that genetic susceptibility, indication for antibiotic treatment, environmental factors, and microbiome diversity all interplay in nuanced ways that require further exploration.

The implications of this study are profound for clinical practice. While prudent and judicious use of antibiotics remains essential to combat antimicrobial resistance and preserve microbial ecology, this research supports the continued use of antibiotics when medically indicated during pregnancy and early infancy. The potential benefits in controlling maternal and infant infections appear to outweigh any minimal risk related to autoimmune disease development. Nevertheless, the authors advocate for targeted follow-up studies that might evaluate subpopulations potentially more vulnerable or gain finer granularity on antibiotic classes, dosages, and timing.

From a technical standpoint, the study’s design exemplifies rigorous epidemiological research by harnessing large-scale administrative datasets to answer complex questions about immune ontogeny and environmental exposures. The retrospective cohort approach facilitated real-world evidence generation with unparalleled statistical power, while mother-child linkage enhanced the accuracy of exposure assessment. However, the researchers acknowledge inherent limitations of observational studies, such as residual confounding and the absence of mechanistic biomarkers, underscoring the need for complementary experimental investigations.

One of the intriguing biological premises underlying past concerns is the impact of antibiotics on the infant gut microbiome—a critical architect of immune education. Disruptions in microbiota composition have been implicated in aberrant immune responses and autoimmunity in animal models. Nonetheless, Shin et al.’s findings suggest that if such microbiome perturbations occur due to antibiotic exposure, they may not translate straightforwardly into clinical autoimmune conditions, or compensatory mechanisms could mitigate potential harm. This invites further research employing metagenomic and immunophenotyping tools to delve deeper into host-microbe interactions.

Moreover, it is essential to interpret the study’s message within the broader context of immune-mediated diseases, which are multifactorial in origin. Genetic predisposition, environmental triggers, lifestyle factors, and stochastic processes collectively shape autoimmune risk. Antibiotic exposure is but one piece of a highly complex puzzle. The study reaffirms the need for personalized medicine approaches that consider individual susceptibility and carefully weigh risks and benefits in therapeutic decision-making during pregnancy and infancy.

Beyond its clinical relevance, this research sets a precedent for future large-scale pharmacoepidemiological studies that harness real-world data to explore early-life exposures. The vast data resource in South Korea provides a model for similar studies globally, enabling more generalizable insights and fostering international collaborations. Such endeavors are vital to deepen our understanding of how modern medical interventions intersect with human biology during critical developmental periods.

In summary, this seminal study by Shin and colleagues offers a reassuring perspective for clinicians, parents, and public health policymakers alike. By demonstrating no observable link between early antibiotic exposure and autoimmune disease risk in children on a nationwide scale, it challenges assumptions and encourages evidence-based antibiotic stewardship during pregnancy and infancy. At the same time, it leaves the door open for continued scientific inquiry into the complex mechanisms underlying immune tolerance and autoimmunity, highlighting the ever-evolving nature of medical knowledge.

As the global scientific community digests these findings, the overarching takeaway is one of cautious optimism. While vigilance remains warranted to minimize unnecessary antibiotic use, this study bolsters confidence that essential treatments in early life can be administered without undue fear of triggering autoimmune diseases. It is an important milestone in the journey toward safeguarding the health of future generations through balanced, data-driven medical care.

Subject of Research: People

Article Title: Exposure to antibiotics during pregnancy or early infancy and the risk of autoimmune disease in children: A nationwide cohort study in Korea

News Publication Date: August 21, 2025

Web References:
https://doi.org/10.1371/journal.pmed.1004677

References:
Choi E-Y, Bea S, Lee H, Choi A, Han JY, Kang EH, et al. (2025) Exposure to antibiotics during pregnancy or early infancy and the risk of autoimmune disease in children: A nationwide cohort study in Korea. PLoS Med 22(8): e1004677.

Image Credits:
neildodhia, Pixabay (CC0)

Keywords: antibiotics, autoimmune diseases, pregnancy, infancy, Type 1 diabetes, juvenile idiopathic arthritis, inflammatory bowel disease, systemic lupus erythematosus, Hashimoto’s thyroiditis, microbiome, immune system, cohort study, epidemiology

The prenatal period is increasingly recognized as a pivotal window during which environmental exposures can fundamentally shape an infant’s immune system trajectory. Antibiotics administered during pregnancy, while often necessary to treat maternal infections, represent a disruptive force to this delicate developmental milieu. Historically, the consequences of such interventions were primarily considered from the standpoint of immediate infection control. However, emerging data suggest a nuanced and potentially far-reaching impact, implicating prenatal antibiotics in alterations of breast milk immunological factors and early-life microbial colonization patterns, both of which are essential to neonatal immune competency.

The study at hand, designed as a case-control translational protocol, aims to comprehensively characterize these effects by evaluating the modulation of breast milk’s immune composition—focusing particularly on secretory IgA—and the subsequent development of neonatal mucosal immunity and microbiome diversity. Secretory IgA, a critical antibody class abundantly present in breast milk, serves as the first line of defense in the neonate’s gut by neutralizing pathogens and fostering a symbiotic relationship with beneficial microbes. Disruption to its concentration or function caused by prenatal antibiotic use could potentially predispose infants to infections, allergic diseases, or long-term immune dysregulation.

Throughout this protocol, the researchers utilize a multidimensional approach, combining clinical observational data with advanced molecular analytics. By enrolling pregnant women who have undergone antibiotic treatment and carefully matched controls, the study captures a comparative perspective that can discern how antibiotics perturb the immune and microbial landscape. This design permits an exploration beyond correlative findings, striving toward causative insights by integrating microbiome sequencing, immunoglobulin quantification, and detailed clinical neonatal outcomes.

One of the novel technical facets of this protocol is the application of high-throughput 16S ribosomal RNA gene sequencing to profile breast milk and neonatal gut microbiota. This technology allows for high-resolution identification of bacterial taxa, their relative abundances, and community dynamics affected by prenatal antibiotic exposure. The ability to map these microbial changes in conjunction with IgA levels provides a multidimensional snapshot of maternal-infant immune crosstalk, offering clues on how microbial ecosystems and host immunity develop in tandem.

Moreover, the protocol incorporates enzyme-linked immunosorbent assays (ELISA) for precise quantification of breast milk IgA, ensuring robust, reproducible measures of this key immune component. The integration of immunological assays with microbiome profiling signifies a methodological leap, enabling a holistic understanding of how antibiotics might dysregulate the protective axis that breast milk confers.

A particularly striking implication of this research is its relevance to the concept of developmental origins of health and disease (DOHaD). Early microbial colonization and immunoglobulin exposure profoundly influence an infant’s risk for disorders such as asthma, eczema, and gastrointestinal diseases. If prenatal antibiotics degrade the protective landscape provided by maternal breast milk and neonatal IgA, delayed microbial maturation or immunodeficiency could ensue. The clinical ramifications thus extend far beyond the neonatal period, potentially affecting lifelong health trajectories.

Compelling scientific narratives also revolve around the translational nature of this study—bridging bench research with bedside application. Understanding these mechanisms opens avenues for the development of targeted interventions, such as maternal probiotic therapies during or after antibiotic treatment, IgA supplementation strategies, or novel breastfeeding support paradigms designed to optimize infant immunity despite prenatal disruptions.

The correction published alongside this protocol formally addresses adjustments in parameters and clarifies procedural protocols, underscoring the authors’ commitment to scientific rigor and transparency. It reflects the evolving nature of translational research where iterative refinements ensure that findings are both valid and clinically actionable.

Importantly, the study protocol also considers confounding variables such as maternal diet, mode of delivery, and postnatal antibiotic exposure, all of which interlace with immune development and microbiome assembly. By accounting for these factors, the researchers aim to isolate the specific influence of prenatal antibiotic exposure, enhancing the precision of their conclusions.

Emerging from the detailed protocol is a narrative that supports the increasingly accepted paradigm that maternal health interventions exert profound impacts on neonatal immune ontogeny. The carefully designed cohort comparisons promise to yield robust data that could ultimately reshape clinical guidelines surrounding antibiotic use in pregnancy, advocating for judicious application balanced against risk and benefit.

This research protocol further paves the way for future longitudinal studies focusing on the durability of prenatal antibiotic effects. Questions remain regarding whether early microbial and immunological disturbances resolve naturally or require therapeutic modulation. Subsequent research could explore supplementation strategies or modulation of breast milk composition to counteract potential deficits introduced prenatally.

Technology-enabled precision immunology and microbiome research embodied in this protocol exemplify the power of interdisciplinary science in addressing complex clinical challenges. It heralds a future in which maternal-fetal medicine incorporates personalized microbiome and immunological assessments into routine prenatal care.

From a public health perspective, the implications are vast. With rising antibiotic use globally, understanding the subtleties of prenatal antibiotic consequences is vital to inform policies that safeguard not only maternal well-being but also neonatal, and by extension, population health.

In summary, the translational study protocol detailed by Pietrasanta and colleagues offers a meticulously conceived pathway towards demystifying the impacts of prenatal antibiotics on breast milk IgA and neonatal microbiome development. By integrating cutting-edge techniques and rigorous cohort design, the research promises to enrich our understanding of early immune programming and microbial colonization, key determinants of lifelong health.

As the scientific community awaits the results emerging from this protocol’s implementation, there is a palpable anticipation for novel insights that could revolutionize approaches to maternal antibiotic administration, breastfeeding support, and neonatal immune care strategies.

The broader implications extend beyond neonatology, touching on microbiology, immunology, and precision medicine, reflecting the complex biological symphony that begins even before birth and resonates throughout life.

Subject of Research: Effect of prenatal antibiotics on breast milk Immunoglobulin A (IgA) levels and neonatal microbiome development.

Article Title: Correction: Effect of prenatal antibiotics on breast milk and neonatal IgA and microbiome: a case-control translational study protocol.

Article References:

Pietrasanta, C., Ronchi, A., Carlosama, C. et al. Correction: Effect of prenatal antibiotics on breast milk and neonatal IgA and microbiome: a case-control translational study protocol.
Pediatr Res (2025). https://doi.org/10.1038/s41390-025-04318-0

Image Credits: AI Generated